Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

Rhea-AI Summary

Viracta Therapeutics (Nasdaq: VIRX), a precision oncology company, announces participation in the Stifel 2023 Targeted Oncology Days on April 26, 2023. President and CEO Mark Rothera and Chief Medical Officer Lisa Rojkjaer, M.D. will conduct a virtual fireside chat at 12:00 p.m. ET. A live webcast will be accessible on the Investors section of Viracta's website and archived for 90 days.

Viracta focuses on treating virus-associated cancers globally. Its lead product candidate, nanatinostat, is part of an oral combination therapy with valganciclovir (Nana-val), targeting subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma and EBV+ nasopharyngeal carcinoma in ongoing clinical trials.

SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 12:00 p.m. ET.

A live webcast of the fireside chat will be available on the Investors section of the Viracta website under "Events and Webcasts" and archived for 90 days.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV⁺) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 trial for the treatment of EBV⁺ recurrent or metastatic nasopharyngeal carcinoma and other EBV⁺ solid tumors. Viracta is also pursuing the application of its “Kick and Kill” approach in other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com

SOURCE Viracta Therapeutics, Inc.

FAQ

When is Viracta's fireside chat at the Stifel 2023 Targeted Oncology Days?

Viracta's fireside chat is scheduled for April 26, 2023, at 12:00 p.m. ET.

Who will represent Viracta at the Stifel oncology event?

Mark Rothera, President and CEO, and Lisa Rojkjaer, M.D., Chief Medical Officer, will represent Viracta.

How can I watch Viracta's fireside chat?

The fireside chat will be available via a live webcast on the Investors section of Viracta's website.

What is Viracta's lead product candidate?

Viracta's lead product candidate is an all-oral combination therapy called Nana-val, consisting of nanatinostat and valganciclovir.

What cancers is Viracta focusing on with its therapies?

Viracta is focusing on virus-associated cancers, particularly targeting EBV-positive lymphomas and nasopharyngeal carcinoma.